Literature DB >> 28815803

Validity of cancer diagnosis in the National Health Insurance database compared with the linked National Cancer Registry in Taiwan.

Wei-Heng Kao1, Ji-Hong Hong1,2,3, Lai-Chu See4, Huang-Ping Yu5, Jun-Te Hsu6, I-Jun Chou7, Wen-Chi Chou8, Meng-Jiun Chiou9, Chun-Chieh Wang1,2, Chang-Fu Kuo9,10.   

Abstract

PURPOSE: We aimed to evaluate the validity of cancer diagnosis in the National Health Insurance (NHI) database, which has routinely collected the health information of almost the entire Taiwanese population since 1995, compared with the Taiwan National Cancer Registry (NCR).
METHODS: There were 26,542,445 active participants registered in the NHI database between 2001 and 2012. National Cancer Registry and NHI database records were compared for cancer diagnosis; date of cancer diagnosis; and 1, 2, and 5 year survival. In addition, the 10 leading causes of cancer deaths in Taiwan were analyzed.
RESULTS: There were 908,986 cancer diagnoses in NCR and NHI database and 782,775 (86.1%) in both, with 53,192 (5.9%) in the NHI database only and 73,019 (8.0%) in the NCR only. The positive predictive value of the NHI database cancer diagnoses was 94% for all cancers; the positive predictive value of the 10 specific cancers ranged from 95% (lung cancer) to 82% (cervical cancer). The date of diagnosis in the NHI database was generally delayed by a median of 15 days (interquartile range 8-18) compared with the NCR. The 1, 2, and 5 year survival rates were 71.21%, 60.85%, and 47.44% using the NHI database and were 71.18%, 60.17%, and 46.09% using NCR data.
CONCLUSIONS: Recording of cancer diagnoses and survival estimates based on these diagnosis codes in the NHI database are generally consistent with the NCR. Studies using NHI database data must pay careful attention to eligibility and record linkage; use of both sources is recommended.
Copyright © 2017 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Taiwan National Health Insurance database; cancer diagnosis; pharmacoepidemiology; validity

Mesh:

Year:  2017        PMID: 28815803     DOI: 10.1002/pds.4267

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  37 in total

1.  Association between gastroesophageal reflux disease and colorectal cancer risk: a population-based cohort study.

Authors:  Je-Ming Hu; Jia-Jheng Wu; Chih-Hsiung Hsu; Yong-Chen Chen; Yu-Feng Tian; Pi-Kai Chang; Chao-Yang Chen; Yu-Ching Chou; Chien-An Sun
Journal:  Int J Colorectal Dis       Date:  2021-04-16       Impact factor: 2.571

2.  Risk of developing a second primary cancer in male breast cancer survivors: a systematic review and meta-analysis.

Authors:  Isaac Allen; Hend Hassan; Eleni Sofianopoulou; Diana Eccles; Clare Turnbull; Marc Tischkowitz; Paul Pharoah; Antonis C Antoniou
Journal:  Br J Cancer       Date:  2022-09-17       Impact factor: 9.075

3.  Evaluation of risk adjustment performance of diagnosis-based and medication-based comorbidity indices in patients with chronic obstructive pulmonary disease.

Authors:  Huei Guo Ie; Chao-Hsiun Tang; Mei-Ling Sheu; Hung-Yi Liu; Ning Lu; Tuan-Ya Tsai; Bi-Li Chen; Kuo-Cherh Huang
Journal:  PLoS One       Date:  2022-07-08       Impact factor: 3.752

4.  Association between Breast Cancer and Second Primary Lung Cancer among the Female Population in Taiwan: A Nationwide Population-Based Cohort Study.

Authors:  Fan-Wen Lin; Ming-Hsin Yeh; Cheng-Li Lin; James Cheng-Chung Wei
Journal:  Cancers (Basel)       Date:  2022-06-16       Impact factor: 6.575

5.  The potential role of nontyphoidal salmonellosis in gastric cancer: a nationwide matched cohort study.

Authors:  Renin Chang; James Cheng-Chung Wei; Mei-Chen Lin; Yao-Min Hung
Journal:  Gastric Cancer       Date:  2020-11-01       Impact factor: 7.370

6.  Increased risk of Alzheimer's disease among patients with age-related macular degeneration: A nationwide population-based study.

Authors:  Li-Yen Wen; Lei Wan; Jung-Nien Lai; Chih Sheng Chen; Jamie Jiin-Yi Chen; Ming-Yen Wu; Kai-Chieh Hu; Lu-Ting Chiu; Peng-Tai Tien; Hui-Ju Lin
Journal:  PLoS One       Date:  2021-05-07       Impact factor: 3.240

7.  Interaction and joint effect of ALT and chronic liver disease on liver cancer in type 2 diabetes patients.

Authors:  Tsai-Chung Li; Chia-Ing Li; Chiu-Shong Liu; Pao-Hsuan Lin; Wen-Yuan Lin; Chih-Hsueh Lin; Sing-Yu Yang; Jen-Huai Chiang; Cheng-Chieh Lin
Journal:  Oncotarget       Date:  2017-10-10

8.  Prostate-selective α antagonists increase fracture risk in prostate cancer patients with and without a history of androgen deprivation therapy: a nationwide population-based study.

Authors:  Wei-Heng Kao; Chang-Fu Kuo; I-Jun Chou; Lai-Chu See; Wen-Kuan Huang; Meng-Jiun Chiou; Weiya Zhang; Michael Doherty; Chun-Chieh Wang; Jun-Te Hsu; Hsien-Hsin Chen; Ji-Hong Hong
Journal:  Oncotarget       Date:  2018-01-02

9.  Urate-lowering treatment and risk of total joint replacement in patients with gout.

Authors:  Chang-Fu Kuo; I-Jun Chou; Lai-Chu See; Jung-Sheng Chen; Kuang-Hui Yu; Shue-Fen Luo; Ao-Ho Hsieh; Weiya Zhang; Michael Doherty
Journal:  Rheumatology (Oxford)       Date:  2018-12-01       Impact factor: 7.580

10.  Type of Androgen Deprivation Therapy and Risk of Dementia Among Patients With Prostate Cancer in Taiwan.

Authors:  Wen-Kuan Huang; Chi-Hung Liu; See-Tong Pang; Jia-Rou Liu; John Wen-Cheng Chang; Chuang-Chi Liaw; Cheng-Lung Hsu; Yung-Chang Lin; Lai-Chu See
Journal:  JAMA Netw Open       Date:  2020-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.